Kaiser U, Neumann K, Havemann K
Philipps-Universität Marburg, Zentrum für Innere Medizin, Abteilung Hämatologie/Onkologie, Marburg, Federal Republic of Germany.
J Cancer Res Clin Oncol. 1993;119(5):301-3. doi: 10.1007/BF01212729.
We report on a 37-year-old female patient with generalised giant-cell tumour of the bone, whose tumour was refractory to conventional chemotherapy. Subsequent treatment with interferon alpha 2a in increasing dosage from 4 x 10(6) IU (three times a week) to 9 x 10(6) IU (three times a week) led to a significant decrease of pulmonary metastases and a stabilisation of the disease after 12 months of treatment. In progressive chemotherapy refractory giant-cell tumour interferon alpha 2a may be of therapeutic benefit.
我们报告了一名37岁患有广泛性骨巨细胞瘤的女性患者，其肿瘤对传统化疗无效。随后使用α-2a干扰素进行治疗，剂量从4×10⁶国际单位（每周三次）逐渐增加至9×10⁶国际单位（每周三次），治疗12个月后，肺部转移灶显著减少，病情得到稳定。对于进展性化疗难治性骨巨细胞瘤，α-2a干扰素可能具有治疗益处。
